GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immunocore Holdings PLC (NAS:IMCR) » Definitions » Revenue

Immunocore Holdings (Immunocore Holdings) Revenue : $311.8 Mil (TTM As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Immunocore Holdings Revenue?

Immunocore Holdings's revenue for the three months ended in Dec. 2023 was $133.7 Mil. Its revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $311.8 Mil. Immunocore Holdings's Revenue per Share for the three months ended in Dec. 2023 was $2.70. Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $6.24.

Warning Sign:

Immunocore Holdings PLC revenue growth has slowed down over the past 12 months.

During the past 12 months, the average Revenue per Share Growth Rate of Immunocore Holdings was 35.10% per year. During the past 3 years, the average Revenue per Share Growth Rate was 78.20% per year. During the past 5 years, the average Revenue per Share Growth Rate was 609.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.

During the past 6 years, Immunocore Holdings's highest 3-Year average Revenue per Share Growth Rate was 1536.80% per year. The lowest was 78.20% per year. And the median was 903.70% per year.


Immunocore Holdings Revenue Historical Data

The historical data trend for Immunocore Holdings's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immunocore Holdings Revenue Chart

Immunocore Holdings Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Revenue
Get a 7-Day Free Trial 33.64 40.48 48.52 212.38 315.73

Immunocore Holdings Quarterly Data
Dec18 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 95.84 54.06 60.31 63.72 133.72

Competitive Comparison of Immunocore Holdings's Revenue

For the Biotechnology subindustry, Immunocore Holdings's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Immunocore Holdings's Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Immunocore Holdings's Revenue distribution charts can be found below:

* The bar in red indicates where Immunocore Holdings's Revenue falls into.



Immunocore Holdings Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $311.8 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Immunocore Holdings  (NAS:IMCR) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


Immunocore Holdings Revenue Related Terms

Thank you for viewing the detailed overview of Immunocore Holdings's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Immunocore Holdings (Immunocore Holdings) Business Description

Traded in Other Exchanges
Address
92 Park Drive, Milton Park, Abingdon, Oxfordshire, GBR, OX14 4RY
Immunocore Holdings PLC is a late-stage biotechnology company engaged in the development of a novel class of TCR bispecific immunotherapies for the treatment of cancer, infectious and autoimmune diseases. Its geographical segments are the United Kingdom and the United States, of which the majority of its revenue comes from the United States.